Результаты поиска

A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.

OBJECTIVE: To analyse the durability of response for patients with non-muscle-invasive bladder cancer (NMIBC) refractory to bacille Calmette-Guérin (BCG) therapy and treated with intravesical docetaxel in a combined induction and maintenance regimen. PATIENTS AND METHODS: A previous phase I trial showed docetaxel to be safe for intravesical therapy, with no systemic absorption and minimal toxicity after six weekly instillations for patients with BCG-refractory NMIBC. In that trial, docetaxel gave a 56% complete response (CR) rate at 12 weeks, but the durability was only 22%. Thus a second gro…

Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.

PURPOSE: Standard treatment for advanced non-small cell lung cancer (NSCLC) consists of platinum based combination chemotherapy but efficacy is limited and treatment can be toxic. This trial evaluated a weekly regimen of docetaxel and gemcitabine for advanced NSCLC. The primary endpoint was objective response rate. Other endpoints were 1-year survival, median survival, median duration of response, median disease-free progression, safety, and quality of life. PATIENTS AND METHODS: Fifty patients with advanced NSCLC were treated. Patients received docetaxel (1 per week, 36 mg/m(2)) weeks 1-6 an…

[A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP].

We report a case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP. A 52-year-old male was diagnosed with type 3 gastric cancer of angulus (poorly differentiated adenocarcinoma) with left neck, Virchow, mediastinal and abdominal lymph nodes metastases. The patient was treated with 5 courses of M-FLP (MTX + 5-FU + LV + CDDP), and the effect of this therapy was PR, but the tumor was chemoresistant to the sixth course of this therapy. After 7 courses of M-FLP, docetaxel (TXT) with low-dose FP (5-…

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.

Six phase II studies have been conducted in the United States and Europe using docetaxel (Taxotere; Rhone-Poulenc Rorer, Antony, France) for advanced non-small cell lung cancer. One hundred eighty chemotherapy-naive patients in four studies and 88 patients who failed prior platinum-containing chemotherapy in two studies were treated with docetaxel 75 to 100 mg/m2 intravenously over 1 hour every 3 weeks. Fifty-nine percent of patients had adenocarcinoma and 82% had stage IV disease. At a dose of 100 mg/m2, 30% of evaluable chemotherapy-naive patients (27% of the intent-to-treat population) and …

Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study.

PURPOSE: Docetaxel (DTX) causes skin toxicities despite dexamethasone-based supportive care, and no established adjunctive primary prophylaxis exists. We assessed whether desloratadine, a peripheral H1-receptor antagonist with anti-inflammatory properties, was associated with DTX-related skin toxicities in early-stage breast cancer. METHODS: This single-center retrospective cohort included 143 patients with stage I-III breast cancer receiving perioperative DTX-based chemotherapy (75 mg/m2 every 3 weeks) with dexamethasone premedication. Desloratadine (5 mg daily from the morning after first D…

Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine/Docetaxel in BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study.

OBJECTIVE: To investigate the oncological and patient-reported outcomes (PROs) of patients receiving sequential gemcitabine/docetaxel (Gem/Doce) for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). DESIGN, SETTING, AND PARTICIPANTS: Patients enrolled in prospective databases at two academic medical institutions who received Gem/Doce -for BCG-unresponsive NMIBC between January 2021 and January 2026 were included. The primary outcome was the 3-mo and 12-mo high-grade recurrence-free survival (HGRFS). Secondary outcomes included progression-free survival (P…

Therapeutic outcomes of PD-1 blockade-related regimens versus docetaxel in previously immunotherapy-treated advanced non-small cell lung cancer: a retrospective, exploratory study.

BACKGROUND: The optimal treatment strategy for patients with advanced non-small cell lung cancer (NSCLC) following progression on initial immune checkpoint inhibitors (ICIs) therapy remained poorly defined. The present study aimed to identify the therapeutic outcomes of PD-1 blockade-based regimens versus docetaxel in previously immunotherapy-treated advanced NSCLC retrospectively. METHODS: Patients with advanced NSCLC who failed prior PD-1/PD-L1 blockades therapy between January 2019 and December 2025 were screened retrospectively. A total of 64 patients who received PD-1 blockade-related re…

Pharmacologic synergy versus independent action in androgen receptor-axis-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysis.

BACKGROUND: Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and androgen receptor-axis-targeted agents (ARATs) has exhibited survival benefits in metastatic hormone-sensitive prostate cancer (mHSPC). Whether these benefits originate from pharmacologic synergy or independent drug action (IDA) remains unclear. METHODS: Using reconstructed individual patient data from phase III trials, we applied a copula-based independent-action model to compare observed triplet outcomes with counterfactual predictions derived from docetaxel- and ARAT-based doublets. The primary analysi…

Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA).

PURPOSE: Breast cancer is the leading cause of death in Nigerian women. Clinical trials are required to provide evidence for treatment. We aimed to generate efficacy data to support the shift in local practice of neoadjuvant therapy for breast cancer. METHODS: A one-stage, phase II feasibility, single-arm study design was used. Treatment-naïve patients with clinically nonmetastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer received four cycles of neoadjuvant docetaxel with subcutaneous trastuzumab (T + scH). Patients with complete clinical response underwent surge…

Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial.

BACKGROUND: A multi-centre, 2-part, phase II study assessed adding rezvilutamide (a novel androgen receptor antagonist) to docetaxel in abiraterone-refractory, metastatic castration-resistant prostate cancer (mCRPC) patients who were naive to chemotherapy. Herein, we report results from part 1. METHODS: Part 1 encompassed both dose-escalation and dose-expansion phases. Eligible patients received oral rezvilutamide (160/240 mg, once daily [QD]) plus intravenous docetaxel (75 mg/m2, on the first day of every 3-week cycle) for more than 10 cycles, followed by maintenance with rezvilutamide monot…

Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.

OBJECTIVES: To evaluate whether extracellular volume (ECV) fraction derived from contrast-enhanced computed tomography (CT) is associated with recurrence risk in patients with treatment-naïve high-risk non-muscle-invasive bladder cancer (HR-NMIBC) receiving intravesical gemcitabine/docetaxel (Gem/Doce) therapy. PATIENTS AND METHODS: This retrospective cohort study, conducted at a tertiary referral centre, included 103 patients with HR-NMIBC treated with intravesical Gem/Doce between 2012 and 2024. All patients underwent pre-resection contrast-enhanced CT with an equilibrium phase (~3 min post…

Preoperative assessment using a scoring system after neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer: Who can avoid surgery?

Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil (DCF) is highly effective for advanced esophageal squamous cell carcinoma, and patients with a good response sometimes desire to avoid surgery. The aim of this single-center, retrospective study was to predict the probability of residual tumors using a newly devised scoring system and identify conditions that may obviate the need for surgery. Between January 2017 and March 2024, 106 patients received NAC with DCF, followed by radical resection at our institution. After NAC, patients underwent multimodal assessments to…

Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.

Although phase II trials have shown that adding docetaxel to S-1/oxaliplatin (DOS) improves pathological response in HER2-negative locally advanced gastric cancer (LAGC), robust real-world evidence comparing DOS with the standard S-1/oxaliplatin (SOX) regimen is lacking. We retrospectively reviewed 1283 consecutive patients with cT2N+ or cT3-4NanyM0, HER2-negative gastric adenocarcinoma treated with ≥2 cycles of DOS (n = 461) or SOX (n = 822) at four high-volume Chinese centers between 2010 and 2024. To address confounding, we applied propensity-score matching (PSM, 1:1) and inverse probabilit…

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

PURPOSE: The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non-small cell lung cancer (NSCLC). METHODS: Patients received Dato-DXd 6 mg/kg or docetaxel 75 mg/m2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Objective response rate, duration of response, and safety were secondary end points. RESULTS: In total, 299 and 305 patients were randomly assigned to receive Dato-DXd or docetax…

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

PURPOSE: The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported. METHODS: Patients were randomly assigned 1:1 (stratified by histology, best response to last anti-PD-(L)1-containing regimen, and AGA treatment received or not) to SG (one 10 mg/kg intravenous infusion on days 1 and 8) or docetaxel (one 75 mg/m2 intravenous infus…

Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.

BACKGROUND AND OBJECTIVE: Androgen deprivation therapy (ADT) with salvage radiation therapy (RT) improves survival for patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) for prostate cancer (PC), but many patients suffer further relapse. This study aims to determine the benefit of the combination of ADT, apalutamide, salvage RT, and docetaxel for high-risk PSA recurrent PC. METHODS: STARTAR is a multicenter, investigator-initiated phase 2 trial of men with PSA recurrent PC after RP. The key inclusion criteria included M0 by computed tomography/bone scan,…

Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition.

Human antigen R (HuR), an RNA-binding protein, is implicated in regulating mRNA stability and translation in cancer, especially in triple-negative breast cancer (TNBC), a highly aggressive form. CRISPR/Cas9-mediated HuR knockout (HuR CRISPR) presents a promising genetic therapeutic approach, but it encounters transfection limitations. Docetaxel (DTX), an effective cytotoxic agent against metastatic breast cancer (BC), faces challenges related to vehicle-associated adverse events in DTX formulations. Therefore, we designed multifunctional nanoparticles with pH-sensitive PEG derivatives and targ…

[A Case of Esophageal Squamous Cell Carcinoma with Gastric Intramural Metastasis Showing Pathological Complete Response after Neoadjuvant Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil].

A 75-year-old man presenting with dysphagia was referred to our hospital and diagnosed with advanced esophageal squamous cell carcinoma(ESCC)accompanied by an intramural metastasis in the gastric wall. Following completion of 3 courses of neoadjuvant chemotherapy(NAC)with docetaxel/cisplatin/5-fluorouracil(DCF), the patient underwent minimally invasive esophagectomy with 3-field lymph node dissection. Histopathological examination showed no viable cancer cells in the esophageal and gastric wall, confirming a complete response. The patient was alive with no evidence of disease as of the 5-year …

Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer.

BACKGROUND: The objective of this study was to evaluate the prognostic value of early PSA decline following initiation of second-generation hormone therapy (2nd HT), namely abiraterone acetate or enzalutamide, in patients with taxane-refractory metastatic castrate-resistant prostate cancer (mCRPC) and evaluate utility of this metric in informing intensified surveillance/imaging protocols. METHODS: We retrospectively identified 75 mCRPC patients treated with 2nd HT following docetaxel failure (defined as PSA rise and radiographic progression). Patients were categorized patients into two cohort…

Добавление доцетаксела в гормональную терапию при раке предстательной простаты с низким и высоким содержанием метастатических гормонов: долгосрочное выживание является результатом испытания STAMPEDE.

СТАМПЕД ранее сообщал о том, что использование переднего доцетакселя улучшило общее выживание (OS) для больных раком наивного гормона, начинающих длительную ирогеновую терапию. Мы сообщаем о долгосрочных результатах, стратифицированных метастатическим бременем для пациентов M1. Мы случайно отправили пациентов 2 :: 1 отношение к стандарту обслуживания (SOC; контрольная группа) или SOC + доцетакель. С помощью ретроспективно собранных базовых сканировок, когда таковые имеются, была проведена классификация метастатических заболеваний. При анализе использовались модели регрессии Кокса, скорректиров

Совпадение в аннотации оригинала
BACKGROUND: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. METHODS: We randomly allocated patients in 2 : 1 ratio to standar…